FDA warns on anesthesia and sedation in pregnant women, young children


The US Food and Drug Administration (FDA) is requiring that labels of general anesthetic and sedation drugs contain a new warning about their use in pregnant women during the 3rd trimester, and in children younger than 3 years. The action reflects concern about the effect that these agents may have on development of a child’s brain.

The FDA has been investigating the potential adverse effects of general anesthetic and sedation drugs on development of children’s brains since the first animal study on the topic in 1999. Recent human studies suggest that a single, relatively short exposure to general anesthetic and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning.

The agency is recommending that physicians balance the benefits of appropriate anesthesia against the potential risks in pregnant women and children, particularly for procedures that may last more than 3 hours or if multiple procedures are required in children younger than 3 years.

The drugs affected by the label change are deslurane, etomidate, halothane, isoflurane, ketamine, lorazepam injection, methohexital, midazolam injection and syrup, pentobarbital, propofol, and sevoflurane.


FDA drug safety communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Shocking maternal health findings from 2023 March of Dimes report card | Image Credit: marchofdimes.org
The importance of maternal vaccination | Image Credit: nfid.org.
The importance of diversity in obstetrics | Image Credit: © stanfordchildrens.org
Study confirms efficacy of JADA against postpartum bleeding | Image Credit: © Amy Taneja MD - © Amy Taneja MD - linkedin.com.
Sean Esplin, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.